Lenalidomide in follicular lymphoma-Reference-Cited by-同舟云学术

Lenalidomide in follicular lymphoma

Published:2020-06-11 Issue:24 Volume:135 Page:2133-2136
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Flowers Christopher R.¹,Leonard John P.²³,Fowler Nathan H.¹

Affiliation:

1. Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX;

2. Department of Medicine, Weill Medical College of Cornell University, New York, NY; and

3. New York Presbyterian Hospital, New York, NY

Abstract

Abstract Lenalidomide is an immunomodulatory drug approved in the United States for use with rituximab in patients with relapsed/refractory follicular lymphoma. We reviewed data from trials addressing the safety and efficacy of lenalidomide alone and in combination with rituximab as a first-line therapy and as a treatment of patients with relapsed/refractory follicular lymphoma. Lenalidomide-rituximab has been demonstrated to be an effective chemotherapy-free therapy that improves upon single-agent rituximab and may become an alternative to chemoimmunotherapy.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/135/24/2133/1744055/bloodbld2019001751c.pdf

Reference22 articles.

1. 2016 US lymphoid malignancy statistics by World Health Organization subtypes;Teras;CA Cancer J Clin,2016

2. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma;Maurer;Am J Hematol,2016

3. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience;Tan;Blood,2013

4. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma;Marcus;Blood,2005

5. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study;Salles;Blood,2008

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improved Side Effect Profile of Alternate-Day Dosing of Lenalidomide;Cureus;2024-03-01

2. The Spectrum of CAR T Assets in Development: Similarities and Differences;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21

3. Drug-Loaded Biomimetic Carriers for Non-Hodgkin’s Lymphoma Therapy: Advances and Perspective;ACS Biomaterials Science & Engineering;2024-01-31

4. Programmed cell death in tumor immunity: mechanistic insights and clinical implications;Frontiers in Immunology;2024-01-12

5. The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma;Experimental Hematology & Oncology;2023-08-14